139 related articles for article (PubMed ID: 29949502)
1. Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model.
Neves DV; Vieira CP; Rocha A; Lanchote VL
J Pharm Pharm Sci; 2018; 21(1):236-246. PubMed ID: 29949502
[TBL] [Abstract][Full Text] [Related]
2. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
4. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
Takeuchi K; Sugiura T; Umeda S; Matsubara K; Horikawa M; Nakamichi N; Silver DL; Ishiwata N; Kato Y
Drug Metab Dispos; 2011 Jun; 39(6):1088-96. PubMed ID: 21422191
[TBL] [Abstract][Full Text] [Related]
7. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
Farrell C; Hayes SC; Wire M; Zhang J
Br J Clin Pharmacol; 2014 Mar; 77(3):532-44. PubMed ID: 24117976
[TBL] [Abstract][Full Text] [Related]
9. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.
Chen J; Xu Y; Lou H; Jiang B; Shao R; Yang D; Hu Y; Ruan Z
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):427-436. PubMed ID: 33779967
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.
Wire MB; McLean HB; Pendry C; Theodore D; Park JW; Peng B
Antimicrob Agents Chemother; 2012 Jun; 56(6):2846-51. PubMed ID: 22391553
[TBL] [Abstract][Full Text] [Related]
12. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Wire MB; Fang L; Hussaini A; Kleha JF; Theodore D
Antimicrob Agents Chemother; 2014 Nov; 58(11):6704-9. PubMed ID: 25155600
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy.
Cheng THT; Tsui TKC; Kwok JSS; Lit LCW; Wong EYL; Kam RKT; Grote-Koska D; Staaden A; Okada H; Fuke N; Wong RSM; Li CK; Chan MHM
Clin Chem Lab Med; 2020 Sep; 58(10):1713-1723. PubMed ID: 31584871
[TBL] [Abstract][Full Text] [Related]
15. A simple HPLC assay for determining eltrombopag concentration in human serum.
Yanagimachi N; Obara N; Sakata-Yanagimoto M; Chiba S; Doki K; Homma M
Biomed Chromatogr; 2021 May; 35(5):e5049. PubMed ID: 33314287
[TBL] [Abstract][Full Text] [Related]
16. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Zhang J; Thapar M; Farrell C; Wire MB
Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects.
Deng Y; Madatian A; Wire MB; Bowen C; Park JW; Williams D; Peng B; Schubert E; Gorycki F; Levy M; Gorycki PD
Drug Metab Dispos; 2011 Sep; 39(9):1734-46. PubMed ID: 21646437
[TBL] [Abstract][Full Text] [Related]
18. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
Gibiansky E; Zhang J; Williams D; Wang Z; Ouellet D
J Clin Pharmacol; 2011 Jun; 51(6):842-56. PubMed ID: 20663993
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study.
Maddela R; Gajula R; Pilli NR; Siddiraju S; Maddela S; Makula A
J Pharm Biomed Anal; 2014 Sep; 98():68-73. PubMed ID: 24887483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
